Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice

Neuroscience Letters

Volumn 258, Issue 3, 1998, Pages 155-158

  Ribeiro, Sandro J ^a   De Lima, Thereza C M ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Trp7 Ala8 NKA((4 10)); Naloxone; Plus maze; Senktide; SR 142801; Tachykinin

Indexed keywords

NALOXONE; NEUROKININ 3 RECEPTOR AGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROKININ A [4-10][7 TRYPTOPHAN 8 BETA ALANINE]; NEUROKININ A DERIVATIVE; OPIATE ANTAGONIST; OSANETANT; SENKTIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EXPERIMENTAL MODEL; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MICE; NALOXONE; NARCOTIC ANTAGONISTS; RECEPTORS, NEUROKININ-3;

EID: 0032564654     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00880-5     Document Type: Article

References (31)

1. Agmo A., Galvan A., Heredia A., Morales M. Naloxone blocks the anti-anxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology. 120:1995;186-194.
2. Cantarella P.A., Chahl L.A. Acute effects of morphine on substance P concentrations in micro-dissected regions of guinea-pig brain. Behav. Pharmacol. 7:1996;470-476.
3. Belzung C., Agmo A. Naloxone potentiates the effects of sub-effective doses of anxiolytic agents in mice. Eur. J. Pharmacol. 323:1997;133-136.
4. Donaldson L.F., Haskell C.A., Hanley M.R. Functional characterization by heterologous expression of a novel cloned tachykinin peptide receptor. Biochem. J. 320:1996;1-5.
5. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharmacol. Assoc. 46:1957;208-210.
6. File S.E. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav. 58:1997;747-752.
7. Geyer M.A., Russo P.V., Masten V.L. Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol. Biochem. Behav. 25:1986;277-288.
8. Graeff F.G. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Brazilian J. Med. Biol. Res. 27:1994;811-829.
9. Harro J., Vasar E., Bradwejn J. CCK in animal and human research. Trends Pharmacol. Sci. 14:1993;244-249.
10. Helke C.J., Krause J.E., Mantyh P.W., Couture R., Bannon M.J. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors and regulatory mechanisms. FASEB J. 4:1990;1606-1615.
11. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1995;21-30.
12. Laursen S.E., Belknap J.P. Intracerebroventricular injections in mice: some methodological refinements. J. Pharmacol. Methods. 16:1986;155-157.
13. Liebsch G., Landgraf R., Gerstberger R., Probst J.C., Wotjak C.T., Engelmann M., Holsboer F., Montkowski A. Chronic infusion of a CRH(1) receptor anti-sense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59:1995;229-239.
14. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
15. Maggio J.E. Tachykinins. Ann. Rev. Neurosci. 11:1988;13-28.
16. Magoul R., Tramu G. Tachykinin-induced changes in b-endorphin gene expression in the rat arcuate nucleus. Neurosci. Lett. 223:1997;93-96.
17. Mansour A., Fox C.A., Akil H., Watson S.J. Opioid receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurcsci. 18:1995;22-29.
18. Motta V., Penha K., Brandão M.L. Effects of microinjections of μ and κ receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test. Psychopharmacology. 120:1995;470-474.
19. Nakanishi S. Mammalian tachykinin receptors, Annu. Rev. Neurosci. 14:1991;123-136.
20. Pratt J.A. The neuroanatomical basis of anxiety. Pharmacol. Ther. 55:1992;149-181.
21. Privette T.H., Terrian D.M. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology. 118:1995;444-450.
22. 3 receptor involvement in the modulation of anxiety, Neuropeptides, (1998) submitted.
23. Smith G.S.T., Savery D., Marden C., Costa J.J.L., Averill S., Priestley J.V., Rattray M. Distribution of messenger RNAs encoding enkephalin, substance P, somatostatin, galanin, vasoactive intestinal polypeptide, neuropeptide Y and calcitonin gene-related peptide in the midbrain periaqueductal grey in the rat. J. Comp. Neurol. 350:1994;23-40.
24. 2 receptor antagonists in the mouse light-dark box. Eur. J. Pharmacol. 250:1993;11-12.
25. Strohle A., Jahn H., Montkowski A., Liebsch G., Boll E., Landgraf R., Holsboer F., Wiedemann K. Central and peripheral administration of atriopeptin is anxiolytic in rats. Neuroendocrinology. 65:1997;210-215.
26. Teixeira R.M., Santos A.R.S., Ribeiro S.J., Calixto J.B., Rae G.A., De Lima T.C.M. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14.
27. Tsuda M., Suzuki T., Misawa M., Nagase H. Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur. J. Pharmacol. 307:1996;7-14.
28. 2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology. 121:1995;186-191.
29. Wettstein J.G., Earley B., Juniens J.L. Central nervous system pharmacology of neuropeptide Y. Pharmacol. Ther. 65:1995;397-414.
30. Yip J., Chahl L.A. Localization of Fos-like immuno-reactivity induced by the NK3 tachykinin receptor agonist, senktide, in the guinea-pig brain. Br. J. Pharmacol. 122:1997;715-725.
31. 1) antagonists CP-96,345 and RP 67580 in Swiss albino mice in the black and white box. Neurosci. Lett. 151:1993;64-66.